WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013148919) TREATMENT OF MULTIPLE MYELOMA
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/148919 International Application No.: PCT/US2013/034225
Publication Date: 03.10.2013 International Filing Date: 28.03.2013
IPC:
A61K 31/4184 (2006.01) ,A61K 31/4406 (2006.01) ,A61K 45/06 (2006.01) ,A61P 35/00 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE[US/US]; 1800 Grant Street, 8th Floor Denver, CO 80203, US
Inventors: LIU, Bolin; US
Agent: VALLA, S., Maurice; Baker & Hostetler LLP Cira Centre, 12th Floor 2929 Arch Street Philadelphia, PA 19104-2891, US
Priority Data:
61/618,54830.03.2012US
61/726,29614.11.2012US
Title (EN) TREATMENT OF MULTIPLE MYELOMA
(FR) TRAITEMENT DU MYÉLOME MULTIPLE
Abstract: front page image
(EN) The present disclosure pertains to methods, dosage forms, and kits for use in the treatment of multiple myeloma in a subject. For example, methods are provided for the treatment of multiple myeloma using a combination of a class I inhibitor of histone deacetylase, such as entinostat, and an antineoplastic alkylating agent, such as bendamustine. The combination of the class I inhibitor of histone deacetylase and the antineoplastic alkylating agent synergistically induces potent anti-proliferative and anti-survival effects in cancer cells, and represents a novel therapeutical approach for treating multiple myeloma, for example.
(FR) La présente invention concerne des procédés, des formes posologiques, et des kits destinés à être utilisés dans le traitement du myélome multiple chez un sujet. Par exemple, l'invention concerne des procédés pour le traitement du myélome multiple à l'aide d'une combinaison d'un inhibiteur de l'histone désacétylase de classe I, tel que l'entinostat, et un agent d'alkylation antinéoplasique, tel que la bendamustine. La combinaison d'un inhibiteur de l'histone désacétylase de classe I et l'agent alcoylant antinéoplasique induit de manière synergique de puissants antiprolifératifs et des effets anti-survie dans les cellules cancéreuses, et représente une nouvelle approche thérapeutique pour le traitement du myélome multiple, par exemple.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)